Campus Chemical Instrument Center, Mass Spectrometry & Proteomics Facility, The Ohio State University, Columbus, USA ...
The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...
That pathway involves a chain reaction of events from a lipid called sphingosine-1-phosphate (S1P), protein kinase M zeta ...
AbbVie’s off-patent TNF blocker is, however, now being succeeded by cheaper biosimilars, namely Boehringer Ingelheim’s ...
FTY720 is a structural analogue of sphingosine that, after conversion to the biologically active FTY720-phosphate molecule, binds with high affinity to sphingosine-1-phosphate receptors to act as ...
Introduction: Defective elastic lamellae and smooth muscle cell (SMC) accumulation are characteristics of diverse obstructive arterial diseases (e.g., atherosclerosis, pulmonary hypertension, and ...
FTY720 (fingolimod) is a structural analogue of sphingosine, an endogenous lysophospholipid, which targets sphingosine-1-phosphate receptors after biotransformation to FTY720-phosphate.